IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Purchased by IFM Investors Pty Ltd

IFM Investors Pty Ltd raised its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 8.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,947 shares of the company's stock after acquiring an additional 1,501 shares during the quarter. IFM Investors Pty Ltd's holdings in IDEXX Laboratories were worth $7,957,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the business. SBI Securities Co. Ltd. purchased a new stake in IDEXX Laboratories in the fourth quarter valued at approximately $97,000. Steward Partners Investment Advisory LLC grew its stake in shares of IDEXX Laboratories by 9.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,436 shares of the company's stock valued at $1,007,000 after buying an additional 218 shares during the period. Proficio Capital Partners LLC acquired a new stake in shares of IDEXX Laboratories during the 4th quarter worth $62,391,000. Cullen Frost Bankers Inc. increased its holdings in shares of IDEXX Laboratories by 1.5% during the 4th quarter. Cullen Frost Bankers Inc. now owns 3,617 shares of the company's stock worth $1,495,000 after buying an additional 52 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of IDEXX Laboratories in the 4th quarter worth $71,893,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on IDXX shares. Stifel Nicolaus upped their price target on shares of IDEXX Laboratories from $510.00 to $540.00 and gave the stock a "hold" rating in a research report on Wednesday, July 2nd. Leerink Partners upped their target price on IDEXX Laboratories from $515.00 to $580.00 and gave the stock an "outperform" rating in a research report on Wednesday, June 11th. Jefferies Financial Group assumed coverage on IDEXX Laboratories in a research note on Tuesday, July 1st. They issued a "buy" rating and a $625.00 target price for the company. Morgan Stanley increased their price objective on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a research report on Monday, May 5th. Finally, Wall Street Zen lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $558.11.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director M Anne Szostak sold 1,260 shares of IDEXX Laboratories stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total value of $645,548.40. Following the completion of the transaction, the director directly owned 1,801 shares of the company's stock, valued at approximately $922,724.34. The trade was a 41.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.98% of the company's stock.

IDEXX Laboratories Stock Down 0.3%

NASDAQ IDXX traded down $1.45 during trading hours on Monday, reaching $545.56. 448,551 shares of the company traded hands, compared to its average volume of 646,147. The stock has a market capitalization of $43.87 billion, a PE ratio of 50.42, a PEG ratio of 3.99 and a beta of 1.54. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $557.09. The company has a 50 day moving average of $510.63 and a two-hundred day moving average of $455.17. The company has a current ratio of 1.16, a quick ratio of 0.81 and a debt-to-equity ratio of 0.31.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping the consensus estimate of $2.93 by $0.03. The company had revenue of $998.43 million during the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The business's revenue was up 3.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.71 EPS. As a group, equities analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.